Clinical Trials Browser

Completed × Interventional × camrelizumab × Clear all

NCT05099848 2026-05-22

A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT04768075 2026-05-20

Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC

Phase 3 Completed

Carcinoma, Non-Small-Cell Lung

NCT05213884 2026-04-24

The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT03083041 2026-03-03

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

Phase 2 Completed

210 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT03092895 2026-01-29

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

Phase 2 Completed

157 enrolled 17 charts

Gastrointestinal

Advanced Primary Liver Cancer

NCT03813784 2025-09-16

A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy

Phase 3 Completed

Gastrointestinal

Stomach Neoplasms

NCT04680988 2025-08-05

A Study of SHR-1210± SHR-1020 Versus Chemotherapy in Patients With Recurrent or Metastatic Cervical Cancer

Phase 2 Completed

Uterine Cervical Neoplasms, Recurrence

NCT05156970 2025-07-31

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck

NCT07053215 2025-07-08

Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC

Phase NA Completed

Carcinoma, Non-Small-Cell Lung

NCT04625803 2025-06-17

Neoadjuvant Therapy for Locally Advanced Colon Cancer

Phase 2 Completed

64 enrolled 11 charts

Gastrointestinal

Colonic Neoplasms

NCT04195828 2025-04-01

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

Phase 2 Completed

Gastrointestinal

Advanced Gastric Cancer

NCT04510064 2025-03-12

Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT05236699 2025-02-14

CCGLC-005

Phase 2 Completed

Gastrointestinal

Cholangiocarcinoma

NCT04649476 2025-01-10

NEOPBOSCC

Phase 2 Completed

68 enrolled 16 charts

Squamous Cell Carcinoma of Head and Neck

NCT05355168 2024-12-31

Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Drug-Related Side Effects and Adverse Reactions

NCT03878472 2024-12-16

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT05003700 2024-11-05

Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma

Phase 2 Completed

Gastrointestinal

Carcinoma, Hepatocellular

NCT03417895 2024-08-07

PASSION

Phase 2 Completed

59 enrolled 17 charts

Small Cell Lung Carcinoma

NCT04613674 2024-03-27

A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Phase 3 Completed

Triple Negative Breast Neoplasms

NCT03558191 2024-03-15

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Phase 2 Completed

156 enrolled 13 charts

Nasopharyngeal Carcinoma

NCT04694183 2024-02-07

The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer

Phase 2 Completed

Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

NCT03764293 2024-02-06

A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC

Phase 3 Completed

543 enrolled 13 charts

Neoplasm Metastasis

NCT03155425 2024-02-01

PD-1 Antibody SHR-1210 in Patients With Relapsed or Refractory Classic Hodgkin's Lymphoma

Phase 2 Completed

75 enrolled 10 charts

Hodgkin Disease

NCT04720131 2024-01-30

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms

NCT03099382 2024-01-22

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Phase 3 Completed

457 enrolled 9 charts

Gastrointestinal

Esophageal Neoplasms

NCT03472365 2024-01-11

A Study of SHR-1210 in Combination With Capecitabine + Oxaliplatin or Apatinib in Treatment of Advanced Gastric Cancer

Phase 2 Completed

67 enrolled 12 charts

Gastrointestinal

Stomach Neoplasms

NCT04805736 2024-01-05

Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

Phase 2 Completed

Breast Neoplasms

NCT04393506 2023-11-22

Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma

Phase 1 Completed

Mouth Neoplasms

NCT04346381 2023-09-18

Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor

Phase 2 Completed

Other solid neoplasm

Solid Tumor

NCT05809336 2023-04-12

Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors

Phase 2/3 Completed

Other solid neoplasm

Advanced Solid Tumor

NCT03816553 2023-04-11

SHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer

Phase 2 Completed

Uterine Cervical Neoplasms

NCT02721589 2023-02-28

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 by Advanced Solid Tumor Subjects

Phase 1 Completed

Other solid neoplasm

Advanced Solid Tumors

NCT02742935 2023-02-27

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Phase 1 Completed

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms

NCT03691090 2022-12-07

Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer

Phase 3 Completed

Gastrointestinal

Advanced Esophageal Cancer

NCT03755440 2022-09-21

PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.

Phase 2 Completed

Gastrointestinal

Stomach Neoplasms

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

Phase 1 Completed

Triple Negative Breast Neoplasms

NCT03121716 2022-07-12

A Study to Evaluate the Safety and Efficacy of SHR-1210, Gemcitabine and Cis-platinum by R/M NPC Subjects

Phase 1 Completed

Nasopharyngeal Carcinoma

NCT04047017 2021-07-30

GTN

Phase 2 Completed

Recurrence, Gestational Trophoblastic Disease

NCT04642664 2021-06-03

ACABC

Phase 2 Completed

Gastrointestinal

Biliary Tract Neoplasms, Cholangiocarcinoma

NCT04225364 2021-02-02

Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT03394287 2020-10-23

A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBC

Phase 2 Completed

Breast Neoplasms

NCT03187314 2020-08-17

Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer

Phase 2 Completed

Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Diseases, Esophageal Neoplasms

NCT03134872 2020-06-09

A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC

Phase 3 Completed

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03359018 2020-05-19

APFAO

Phase 2 Completed

Osteosarcoma

NCT03222440 2019-12-04

Combination of Radiotherapy and SHR-1210 to Treat Patients With ESCC

Phase NA Completed

Gastrointestinal

Esophageal Neoplasms

NCT02492789 2019-09-30

A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients

Phase 1 Completed

Other hematologic neoplasm

Hematologic Neoplasms